Chronic hepatitis C in African Americans

Area of Science:

• Hepatology
• Infectious Diseases
• Clinical Research

Background:

• Hepatitis C virus (HCV) infection disproportionately affects African Americans compared to other racial groups.
• African Americans with HCV often present with genotype 1, high viral loads, and a slower progression to cirrhosis, but an increased risk of hepatocellular carcinoma post-cirrhosis.
• Underrepresentation in clinical trials has limited understanding of HCV in this population.

Purpose of the Study:

• To investigate the differences in hepatitis C virus natural history and treatment outcomes in African Americans.
• To highlight the observed disparities in sustained virologic response to antiviral therapies.

Main Methods:

• Analysis of existing clinical data and trial results concerning hepatitis C virus infection in African Americans.
• Comparison of disease progression, viral load, and treatment efficacy across different racial groups.

Main Results:

• African Americans exhibit a higher prevalence of hepatitis C virus infection.
• Despite slower cirrhosis progression, African Americans face a higher risk of hepatocellular carcinoma after cirrhosis develops.
• Consistently lower sustained virologic response rates were observed in African Americans undergoing interferon monotherapy, combination interferon plus ribavirin, and peginterferon plus ribavirin therapies.

Conclusions:

• African Americans experience unique patterns in hepatitis C virus natural history and demonstrate reduced response to current antiviral treatments.
• The underlying reasons for these observed differences require further investigation and targeted research efforts.